ArticleMolecular imaging2010
In vivo magnetic resonance imaging and optical imaging comparison of viable and nonviable mesenchymal stem cells with a bifunctional label.
Article in Molecular imaging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Clinical Tracking of Cell Transfer and Cell Transplantation: Trials and Tribulations.Radiology · 2018Review
- The Protein Corona around Nanoparticles Facilitates Stem Cell Labeling for Clinical MR Imaging.Radiology · 2018Article
- Article
- Application prospective of nanoprobes with MRI and FI dual-modality imaging on breast cancer stem cells in tumor.Journal of nanobiotechnology · 2016Review
- Macrophage phagocytosis alters the MRI signal of ferumoxytol-labeled mesenchymal stromal cells in cartilage defects.Scientific reports · 2016Article
- Tracking fusion of human mesenchymal stem cells after transplantation to the heart.Stem cells translational medicine · 2015Article
- Magnetic resonance imaging of stem cell apoptosis in arthritic joints with a caspase activatable contrast agent.ACS nano · 2015Article
- Clinically applicable magnetic-labeling of natural killer cells for MRI of transcatheter delivery to liver tumors: preclinical validation for clinical translation.Nanomedicine (London, England) · 2015Article
- Molecular imaging, biodistribution and efficacy of mesenchymal bone marrow cell therapy in a mouse model of Chagas disease.Microbes and infection · 2014Article
- Biodistribution of mesenchymal stem cell-derived extracellular vesicles in a model of acute kidney injury monitored by optical imaging.International journal of molecular medicine · 2014Article
- MR Imaging of Stem Cell Transplants in Arthritic Joints.Journal of stem cell research & therapy · 2014Article
- Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI.Nanomedicine (London, England) · 2013Article
- In vivo MRI discrimination between live and lysed iron-labelled cells using balanced steady state free precession.European radiology · 2012Article
- Intravenous ferumoxytol allows noninvasive MR imaging monitoring of macrophage migration into stem cell transplants.Radiology · 2012Article
- Magnetic resonance imaging of ferumoxide-labeled mesenchymal stem cells in cartilage defects: in vitro and in vivo investigations.Molecular imaging · 2012Article
- Mesenchymal bone marrow cell therapy in a mouse model of chagas disease. Where do the cells go?PLoS neglected tropical diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
The purpose of this study was to compare viable and nonviable bilabeled mesenchymal stem cells (MSCs) in arthritic joints with magnetic resonance imaging (MRI) and optical imaging (OI). MSCs were labeled with ferucarbotran and DiD. MRI and OI of bilabeled cells were compared with controls. Six rats with arthritis received intra-articular injections of bilabeled viable MSCs into the right knee and nonviable MSCs into the left knee. Animals underwent MRI and OI preinjection and at 4, 24, 48, and 72 hours postinjection. The results were analyzed with a mixed random effects model and Fisher probability. Bilabeled MSCs showed increased MRI and OI signals compared to unlabeled controls (p < .0001). After intra-articular injection, bilabeled MSCs caused significant T2 and T2* effect on MRI and fluorescence on OI up to 72 hours postinjection (p < .05). There was no significant difference between viable and nonviable MSC signal in the knee joints; however, some of the viable cells migrated to an adjacent inflamed ankle joint (p < .05). Immunohistochemistry confirmed viable MSCs in right knee and ankle joints and nonviable MSCs in the left knee. Viable and nonviable cells could not be differentiated with MRI or OI signal intensity but were differentiated based on their ability to migrate in vivo.
Indexed as
Identifiers
20868628PMC3060764W2110212484What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.